NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Lonza Group AG Establishes Global Capability Centre in Hyderabad

Lonza Group AG, a leading contract development and manufacturing organisation, has selected Hyderabad as the location for its new Global Capability Centre (GCC). This strategic decision further solidifies Telangana's position as a prominent global life sciences hub.

Background and Decision

Following months of evaluation and discussions with state leadership, Lonza finalised its decision to establish the GCC in Hyderabad. The company met with Telangana's Industries & Commerce Minister D. Sridhar Babu and Telangana Lifesciences CEO Shakthi M. Nagappan to formally communicate its plan.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Key Figures and Performance

Lonza, founded in 1897, operates across more than 30 sites worldwide with nearly 20,000 employees. The company reported CHF 6.5 billion in sales and CHF 2.1 billion in Core EBITDA in 2022.

Reasons for Selection

Lonza cited Hyderabad's talent pool, quality infrastructure, and supportive industrial ecosystem as key reasons for its selection.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Impact and Future Prospects

The new GCC is expected to generate high-value employment and deepen Hyderabad's integration into the global biopharma value chain. Telangana already hosts a growing concentration of multinational R&D, manufacturing, and digital capability centres, and Lonza's entry further strengthens its standing among global life sciences destinations.

Global Life Sciences Ecosystem

Lonza's investment is the latest in a series of global bets on Hyderabad's life sciences ecosystem, which has been expanding rapidly across biologics, vaccines, CRDMO services, and global capability hubs. With this move, the company joins a cluster of international players leveraging the city's technology base, scientific workforce, and government support.

Investor Takeaway

Investors should consider the long-term growth potential of the life sciences sector in India.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.